Abstract
Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have